This week, analysts’ and traders’ attention is focused on five companies: Palantir, Nvidia, Intuitive Surgical, Las Vegas Sands, and Incyte. Each of them has approached important buy levels, and some are already showing early signs of renewed growth, making them attractive for medium-term and long-term investors.
Palantir (PLTR) continues to strengthen its position in the artificial intelligence sector. The company is delivering impressive revenue and profit growth, with revenue accelerating for nine consecutive quarters. In the third quarter, revenue increased by 63% and EPS rose by 110%. Despite a modest correction after a strong rally, the fundamentals remain robust. The stock price is still below a key entry point, making it sensitive to volatility, but the upside potential remains intact, and Palantir deserves a place on the watchlist.
Nvidia (NVDA), the leader in AI chips, is showing signs of an early bullish impulse. The stock has reclaimed its 50-day moving average, H200 shipments to China are scheduled for February, and a $20 billion deal involving Groq assets strengthens the company’s position. Third-quarter financial results are strong: revenue grew by 62%, EPS by 60%, with further acceleration underway. Nvidia appears ready for another breakout, making it attractive to investors looking for early entry points in the high-tech sector.
Intuitive Surgical (ISRG), a leader in robotic surgery, has emerged from a deep consolidation, posting a strong post-earnings move of +22% in a single week. The key buy point lies in the $582–583 range, while fundamentals remain solid, with EPS up 30% and revenue up 23% in the third quarter. This makes Intuitive Surgical an appealing candidate for medium-term growth.
Incyte (INCY), a biotechnology company, is also showing impressive growth dynamics. The stock has rebounded strongly from its 50-day moving average, with an early entry point at $103.45 and a primary buy point at $109.28. Third-quarter financials are equally strong, with EPS up 111% and sales up 20%, making Incyte one of the most dynamic biotech stories of the year.
Las Vegas Sands (LVS), which operates casinos in Macau and Singapore, is forming a tight consolidation near its 21-day moving average, often a sign of a new base forming. The stock is up 29% year to date and ranks among the sector leaders. This option may appeal to investors who prefer moderately volatile stories with more predictable price action.
Overall, all five companies display strong fundamentals, while the broader market is gradually recovering toward year-end. Each stock is at a different stage of its growth cycle: NVDA and ISRG appear most ready to extend their trends, Palantir and Incyte are potential breakout candidates after a pause, and Las Vegas Sands offers a more moderately conservative profile. For a successful entry, it is crucial to closely monitor price action around key buy points. These stories could set the tone for the 2026 investment year, offering opportunities for both capital growth and portfolio diversification across different risk profiles.
All content provided on this website (https://wildinwest.com/) -including attachments, links, or referenced materials — is for informative and entertainment purposes only and should not be considered as financial advice. Third-party materials remain the property of their respective owners.